Shopping Cart
Remove All
Your shopping cart is currently empty
Piritrexim
Copy Product Info
🥰Excellent
Catalog No. T24644Cas No. 72732-56-0
Alias BW 301U
Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
Piritrexim
Copy Product Info🥰Excellent
Purity: 98.50%
Catalog No. T24644Alias BW 301UCas No. 72732-56-0
Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $350 | In Stock | In Stock | |
| 5 mg | $970 | In Stock | In Stock | |
| 25 mg | $1,590 | In Stock | In Stock | |
| 50 mg | $1,980 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.50%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer. |
| Targets&IC50 | Walker 256 cells:0.008 uM(ED50) |
| In vitro | Piritrexim (0.1 to 1.0 microM) was able to inhibit the replication of T.gondii in a mouse peritoneal macrophage model. The addition of sulfadiazine, which alone was ineffective, to piritrexim allowed inhibition of T.gondii replication at lower concentrations of piritrexim than when piritrexim was used alone.[5] |
| In vivo | Piritrexim (25-mg/m2/dose; oral) occurred the myelosuppression and mucositis in 4 of 4 patients but in none of the patients treated at the 15- and 20-mg/m2/dose levels.[6] Piritrexim (20 mg/m2/dose; oral) was rapidly absorbed, with the median time to peak level occurring 1.5 h after an oral dose, and the area under the concentration-time curve (AUC) was linearly related to the dose administered. Trough plasma piritrexim concentration strongly correlated with DLT (P = 0.0016). A trough plasma piritrexim concentration greater than 0.5 microM appeared to be predictive of toxicity. Eleven of 15 patients with trough concentrations exceeding this threshold experienced DLTs.[6] |
| Synonyms | BW 301U |
| Molecular Weight | 325.37 |
| Formula | C17H19N5O2 |
| Cas No. | 72732-56-0 |
| Smiles | CC=1C2=C(N=CC1CC3=C(OC)C=CC(OC)=C3)N=C(N)N=C2N |
| Relative Density. | 1.294g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Piritrexim | purchase Piritrexim | Piritrexim cost | order Piritrexim | Piritrexim chemical structure | Piritrexim in vivo | Piritrexim in vitro | Piritrexim formula | Piritrexim molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.